Skip to nav Skip to content
Cancer survivor ringing the bell at Moffitt Cancer Center

Moffitt's Survival Rates are up to 4x Higher.

The impact of care at NCI Designated Comprehensive Cancer Centers on survival and quality of life is significant.

 

Schedule an Appointment
Certification badges rom Newsweek, NCCN, NCI and Magnet

Earning designation in 2001, Moffitt Cancer Center was Florida's first and continues to be the state's longest-established National Cancer Institute (NCI-designated Comprehensive Cancer Center.) Moffitt has consistently maintained the National Cancer Institute's highest designation, and in 2024, we received our highest score ever. It's a tribute to a team that helps more people survive cancer than any other Florida cancer center. 

Why choose an NCI-designated Comprehensive Cancer Center?

NCI-designated Comprehensive Cancer Centers are recognized for their scientific excellence. They bring together the best scientists and physicians to advance research and patient care. They are a major source of discovering and developing more effective cancer prevention, diagnosis and treatment. According to a population-based study, patients diagnosed with cancers such as pancreatic, lung, and hepatobiliary cancers who were treated at NCI CCCs had a 30% to 70% lower risk of mortality depending on the cancer type.

As one of less than 60 "Comprehensive" Cancer Centers in the U.S., Moffitt has demonstrated strengths across all areas of cancer research and has substantial education, training and community outreach activities that address health disparities.

Call today to schedule an appointment. Call us at 1-888-663-3488 or request an appointment online.

Learn more about NCI's Cancer Center Program

A referral is never required to schedule an appointment at Moffitt. To learn more about the cancers we treat, the services we offer or the oncologists who comprise our experienced team, call 1-888-663-3488 or submit a new patient registration form online.

 

Our patient outcomes often exceed the national average, in part because of ongoing research and a robust portfolio of clinical trials. We are focused on translating our research into new therapies, diagnostics and supportive care for our patients.
John L. Cleveland, Ph.D.